Tempus AI Introduced xH: Its First Whole-Genome Sequencing Test
Tempus AI, Inc. a leader in integrating AI to enhance precision medicine and patient care, has announced the development of its inaugural whole-genome sequencing (WGS) test, xH.
This innovation marks Tempus’ entry into WGS as a platform for identifying clinically significant genetic variants, with a focus on advancing personalized treatments in hematological oncology.
The xH test leverages Tempus’ AI-driven diagnostic platform to support tailored treatment decisions and provide deeper insights into individual genetic profiles.
Initially available for research use only (RUO), xH is set to become clinically available within the next year.
It will also benefit Tempus’ pharmaceutical collaborators by delivering comprehensive data accessible only through whole-genome sequencing.
“Our first product utilizing the complete genome, xH, is designed to uncover critical insights into complex diseases, By scaling WGS, we aim to revolutionize care in hematological oncology and eventually extend to solid tumors, advancing precision medicine and accelerating therapeutic innovation alongside our pharma partners.” – Eric Lefkofsky, Founder and CEO of Tempus
Tempus has tailored xH for myeloid malignancies, delivering highly sensitive detection of clinically relevant genetic alterations in conditions like Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), and Myeloproliferative Neoplasms (MPN).
In a study of 135 patients, xH demonstrated over 98.9% concordance with traditional molecular methods, identifying a wide range of mutation types.
Notably, it detected key structural variants (SVs) and large copy number alterations (CNAs) recommended by clinical guidelines, highlighting its potential to streamline multiple tests into a single, cost-effective assay.
The findings emphasize xH’s ability to enhance personalized treatment strategies by offering a comprehensive genomic profiling solution for myeloid malignancies.
About Tempus
Tempus is a technology-driven company dedicated to advancing precision medicine through artificial intelligence in healthcare. With one of the largest multimodal data libraries globally and a platform to make that data actionable, Tempus delivers AI-powered solutions to personalize patient care while supporting therapeutic discovery and development. Its mission is to enable each patient to benefit from the collective knowledge of prior treatments. Visit tempus.com for more details.
Authors: Robert Huether, Derick Hoskinson, Pavana Anur, Raul Torres, Karl R Beutner, Yan Yang, Kristiyana Kaneva, Kelly A Potts, Andrew Frazier, Iris Braunstein, Brett Mahon, Michael A Thompson, Kate Sasser, Halla Nimeiri, Lewis J Kraft, Francisco M De La Vega, Shira N. Dinner, Guillermo Garcia-Manero
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023